FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301594932> ?p ?o ?g. }

• W4301594932 endingPage "37" @default.
• W4301594932 startingPage "3" @default.
• W4301594932 abstract "Ocular adnexal lymphoma is a relatively rare disease but is one of the most common malignancies in the ocular adnexa, and its incidence is steadily increasing. Ocular adnexal lymphoma consists mainly of four histopathological subtypes of non-Hodgkin B-cell lymphoma: extranodal marginal zone lymphoma (EMZL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and large B-cell lymphoma (LBCL). The clinical characteristics associated with each of the subtypes are not well known due to the sparsity of cases. Furthermore, a number of molecular and phenotypic features have been identified as recurrent and prognosticating in LBCL but are not yet well documented for the ocular adnexal region: concurrent MYC and BCL2 and/or BCL6 rearrangements, MYC/BCL2 double-expressor phenotype (in diffuse large B-cell lymphomas), and MYD88 and CD79B mutations. Therefore, the present PhD study aimed to investigate the clinical features of (1) conjunctival lymphoma by subtype and (2) ocular adnexal MCL in an international multicentre cohort of 307 patients and (3) the clinical and genetic features of ocular adnexal LBCL in 34 Danish patients. This was performed by collecting clinical data on the patients and tissue samples of the LBCLs. The tissue samples were analysed immunohistochemically for phenotype, by allele-specific PCR and Sanger sequencing for the presence of the mutations, and by fluorescence in situ hybridisation for the rearrangements. Statistical analyses were performed to detect correlations with clinical features and survival. The analyses revealed that conjunctival EMZL and FL typically presented in individuals in their 60s as localised unilateral tumour masses and had favourable prognoses (5-year disease-specific survival: 82%-97%). LBCL and MCL were found in all the ocular adnexal structures, with the orbit being the most common location (82% and 58%, respectively). These lymphomas typically presented in patients in their 70s, with MCL having a male predominance. MCLs commonly presented with bilateral lesions and systemic involvement, while LBCLs were unilateral localised tumours. Both subtypes had poor prognoses, with 49%-62% of patients having succumbed to the disease within 5 years. Ocular adnexal LBCLs had presence of concurrent MYC and BCL2 and/or BCL6 rearrangements in 16% of cases, MYC/BCL2 double-expressor phenotype in 44% of diffuse large B-cell lymphomas, and MYD88 ± CD79B mutations in 29% of cases. MYC/BCL2 double-expressor phenotype and MYD88 mutations were associated with adverse prognoses. All in all, the results indicate that the histopathological subtype of ocular adnexal lymphoma is a major outcome predictor. Furthermore, the results underline the importance of analysing the expression of MYC and BCL2 by immunohistochemistry in diffuse large B-cell lymphoma patients and advocate for incorporating the analysis of MYD88 mutations in the routine diagnostic workup of ocular adnexal LBCL. SUMMARY IN DANISH: Lymfomer i øjenregionen (orbita, conjunctiva, øjenlåg, tårekirtel og tåresaek) er relativt sjaeldne tumorer, men er blandt de hyppigste cancerformer i denne region og forekomsten er hastigt stigende. Lymfomer i øjenregionen består hovedsageligt af 4 undertyper af non-Hodgkin B-celle lymfom: ekstranodalt marginal zone lymfom, follikulaert lymfom, storcellet B-celle lymfom og mantle celle lymfom. Grundet sygdommens sjaeldenhed er kliniske karakteristika ved de forskellige lymfomundertyper kun sparsomt undersøgt. Endvidere er der blevet identificeret en raekke prognostisk vigtige molekylaere og faenotypiske kendetegn ved storcellede B-celle lymfomer, som endnu ikke er velundersøgt i øjenregionen. Det drejer sig om samtidig rearrangement i MYC og BCL2 og/eller BCL6, samtidig overekspression af MYC og BCL2 samt MYD88 og CD79B mutationer. Dette ph.d.-studie havde derfor til formål at undersøge de kliniske kendetegn ved (1) mantle celle lymfomer i øjenregionen og (2) de forskellige undertyper af conjunktivale lymfomer i en international kohorte med 307 patienter samt (4) de kliniske, molekylaere og faenotypiske kendetegn ved storcellet B-celle lymfom i 34 danske patienter. Vaevsmaterialet med storcellede B-celle lymfomer blev undersøgt ved hjaelp af immunhistokemi for faenotypen, ved hjaelp af allel-specifik PCR og Sanger sekventering for mutationerne og ved hjaelp af fluorescens in situ-hybridisering for rearrangementerne. Der blev udført statistiske analyser med henblik på at finde eventuelle sammenhaenge med kliniske karakteristika og overlevelse. Analyserne viste, at conjunctivalt ekstranodalt marginal zone lymfom og follikulaert lymfom typisk forekom blandt patienter i 60erne som ensidige tumorer uden spredning og var forbundet med en god prognose (5-års sygdomsspecifik overlevelse på 82-97%). Storcellet B-celle lymfom og mantle celle lymfom blev fundet i samtlige strukturer i øjenregionen med orbita som den hyppigste lokalisation (hhv. 82% og 58%). Disse lymfomundertyper forekom primaert hos patienter i 70erne med overvaegt af maend blandt mantle celle lymfomerne. Mantle celle lymfomerne praesenterede sig typisk som dobbeltsidige laesioner i øjenregionen med systemisk involvering, mens storcellede B-celle lymfomer var ensidige tumorer uden spredning. Begge undertyper havde en dårlig prognose, hvor cirka halvdelen af patienterne døde af sygdommen indenfor 5 år. Genetisk var storcellede B-celle lymfomer i øjenregionen karakteriseret ved betydelig praevalens af MYD88 mutationer (29%), som var forbundet med en dårlig prognose. Rearrangementer i MYC og BCL2 og/eller BCL6 forekom i 16% af tilfaeldene. Derudover havde 44% af diffuse storcellede B-celle lymfomer samtidig overekspression af MYC og BCL2, som var associeret med en dårlig prognose for patienterne. Alt i alt viser resultaterne, at den histologiske undertype er en vigtig prognostisk faktor for lymfomer i øjenregionen. Derudover fremhaever resultaterne vigtigheden af undersøgelsen af MYC/BCL2 faenotypen og implementeringen af MYD88 mutationsundersøgelsen i rutinediagnostikken af storcellede B-celle lymfomer i øjenregionen." @default.
• W4301594932 created "2022-10-05" @default.
• W4301594932 creator A5014266843 @default.
• W4301594932 date "2022-10-01" @default.
• W4301594932 modified "2023-10-05" @default.
• W4301594932 title "Ocular adnexal lymphoma: Subtype‐specific clinical and genetic features" @default.
• W4301594932 cites W1566021942 @default.
• W4301594932 cites W1568270436 @default.
• W4301594932 cites W157156731 @default.
• W4301594932 cites W1603624799 @default.
• W4301594932 cites W1613134190 @default.
• W4301594932 cites W178347807 @default.
• W4301594932 cites W1793743052 @default.
• W4301594932 cites W1799746163 @default.
• W4301594932 cites W1815102102 @default.
• W4301594932 cites W1828648445 @default.
• W4301594932 cites W1874706749 @default.
• W4301594932 cites W1963518605 @default.
• W4301594932 cites W1965794156 @default.
• W4301594932 cites W1969338599 @default.
• W4301594932 cites W1969694757 @default.
• W4301594932 cites W1969837875 @default.
• W4301594932 cites W1970075982 @default.
• W4301594932 cites W1970128919 @default.
• W4301594932 cites W1970132703 @default.
• W4301594932 cites W1973201035 @default.
• W4301594932 cites W1974010997 @default.
• W4301594932 cites W1979816280 @default.
• W4301594932 cites W1981382880 @default.
• W4301594932 cites W1982185661 @default.
• W4301594932 cites W1988241314 @default.
• W4301594932 cites W1992530733 @default.
• W4301594932 cites W1994567562 @default.
• W4301594932 cites W1996279342 @default.
• W4301594932 cites W1997408361 @default.
• W4301594932 cites W1999640894 @default.
• W4301594932 cites W2000219155 @default.
• W4301594932 cites W2000925872 @default.
• W4301594932 cites W2002451995 @default.
• W4301594932 cites W2002534044 @default.
• W4301594932 cites W2003582290 @default.
• W4301594932 cites W2004491321 @default.
• W4301594932 cites W2006070956 @default.
• W4301594932 cites W2007049368 @default.
• W4301594932 cites W2008539598 @default.
• W4301594932 cites W2012537183 @default.
• W4301594932 cites W2016969330 @default.
• W4301594932 cites W2017489130 @default.
• W4301594932 cites W2017883909 @default.
• W4301594932 cites W2018071905 @default.
• W4301594932 cites W2019511165 @default.
• W4301594932 cites W2024040061 @default.
• W4301594932 cites W2027884466 @default.
• W4301594932 cites W2028448084 @default.
• W4301594932 cites W2031019318 @default.
• W4301594932 cites W2033260061 @default.
• W4301594932 cites W2035094814 @default.
• W4301594932 cites W2036038598 @default.
• W4301594932 cites W2037003203 @default.
• W4301594932 cites W2037183009 @default.
• W4301594932 cites W2043226662 @default.
• W4301594932 cites W2043833032 @default.
• W4301594932 cites W2047706679 @default.
• W4301594932 cites W2048037290 @default.
• W4301594932 cites W2049102808 @default.
• W4301594932 cites W2050729712 @default.
• W4301594932 cites W2052861764 @default.
• W4301594932 cites W2052884873 @default.
• W4301594932 cites W2053359352 @default.
• W4301594932 cites W2056295702 @default.
• W4301594932 cites W2056641238 @default.
• W4301594932 cites W2056939983 @default.
• W4301594932 cites W2058015212 @default.
• W4301594932 cites W2062348957 @default.
• W4301594932 cites W2062674533 @default.
• W4301594932 cites W2062683665 @default.
• W4301594932 cites W2064934848 @default.
• W4301594932 cites W2067393779 @default.
• W4301594932 cites W2067752623 @default.
• W4301594932 cites W2070720686 @default.
• W4301594932 cites W2072406584 @default.
• W4301594932 cites W2073888194 @default.
• W4301594932 cites W2077532696 @default.
• W4301594932 cites W2078364559 @default.
• W4301594932 cites W2079316772 @default.
• W4301594932 cites W2081718227 @default.
• W4301594932 cites W2083415414 @default.
• W4301594932 cites W2084785581 @default.
• W4301594932 cites W2086012810 @default.
• W4301594932 cites W2087824134 @default.
• W4301594932 cites W2087885595 @default.
• W4301594932 cites W2088220651 @default.
• W4301594932 cites W2088332148 @default.
• W4301594932 cites W2091685401 @default.
• W4301594932 cites W2094708089 @default.
• W4301594932 cites W2095737226 @default.
• W4301594932 cites W2096197133 @default.
• W4301594932 cites W2097877644 @default.

• next